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OBJECTIVES: The purpose of this study is to provide
economic information comparing olanzapine- and halo-
peridol-treated patients from the subset of French patients
that participated in a large, international, randomised clin-
ical trial in schizophrenia.
METHODS: Patients were evaluated from initiation until
discontinuation of treatment or completion of the 54-week
study. The primary clinical measure was ‘marked clinical
response’ (derived from BPRS total scores). The secondary
measure was ‘marked clinical improvement’ (derived from
CGI severity of illness scores). The primary economic mea-
sure was mean per diem, per patient total direct medical
costs.
RESULTS: A total of 275 French patients were included in
the study. Demographics and other baseline differences be-
tween olanzapine- and haloperidol-treated patients were not
statistically significant. Olanzapine-treated patients (205 
142 days) experienced significantly (p  0.001) longer val-
uation periods than did haloperidol-treated patients (132 
129 days). Olanzapine-treated patients (54%) were signifi-
cantly (p  0.03) more likely to experience a marked clini-
cal response than were haloperidol-treated patients (40%).
Olanzapine-treated patients (69%) were significantly (p 
0.02) more likely to experience a marked clinical improve-
ment than were haloperidol-treated patients (54%). The
mean per diem, per patient total direct medical costs were
statistically lower (p  0.033) for the olanzapine-treated
patients (F619  509) compared with the haloperiodal-
treated patients (F756  478).
CONCLUSION: Olanzapine treatment was associated
with significantly better clinical outcomes and significantly
lower per diem total direct medical costs than was halo-
peridol treatment. The findings in this study indicate that
olanzapine is cost-effective compared with haloperidol for
the treatment of schizophrenia. These findings are of in-
creased relevance in France and add to the existing, large
body of evidence supporting olanzapine’s cost-effective-
ness relative to typical antipsychotics.
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OBJECTIVE: To estimate the cost-effectiveness of using
rt-PA in treating acute ischaemic stroke in the UK.
METHOD: We used a decision-analytic model (Stroke
Outcome Model) to estimate the long term health and cost
consequences of administering rt-PA to patients with acute
ischaemic stroke, based on the pooled results of three ma-
jor trials: ECASS-1, ECASS-2 and NINDS (2044 patients
in total). Long-term consequences of stroke were based on
the Oxfordshire Community Stroke Project. Disability was
defined using the modified Rankin scale (disabled: catego-
ries 3–5). Utilities for disability states were taken from
published studies of stroke survivors. Resource use mea-
sured from a health and social service perspective, was
based on published studies and a panel of clinical experts.
Unit costs (1996) were obtained from national sources.
Costs and health outcomes were discounted at 6% pa.
RESULTS: For patients treated within 6 hours of stroke
onset the probability of symptomatic intracranial haemor-
rhage (SICH) was 12.6% (rt-PA group) and 3.7% (pla-
cebo group). In the absence of SICH the probability of
death within 90 days was 10.1% and 14.1% and the pro-
portion of survivors who were disabled was 38.2% and
49.6% respectively. The model predicted that over 5 years
from the incident stroke patients in the rt-PA group on av-
erage lost 0.04 life-years but gained 0.31 disability-free
life-years and 0.13 QALYs. This resulted in cost savings of
£2,500–£3,000 per treated patient, depending on how
costs of initial acute care were included. Improvements in
health outcome and cost savings were greater for the
group treated with rt-PA within 3 hours of stroke onset.
CONCLUSIONS: Trial results suggest that rt-PA is likely
to be cost saving in patients treated within 6 hours of onset
of acute stroke. A comprehensive analysis needs to con-
sider the fixed costs and wider policy implications of intro-
ducing and maintaining a local thrombolysis service.
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OBJECTIVES: The management of atherothrombotic pa-
tients is a heavy burden on the Health budget. As MI and
IS patients need acute as well as chronic care, a 2-year pe-
riod was considered for studying local treatment patterns
and the resulting costs (hospital & ambulatory costs). The
overall cost of managing an ischemic event (MI,IS) was di-
vided in acute (Ac) and follow-up (Fup) costs over 2 years.
METHODS: France(F), Belgium(B), Switzerland(CH), Swe-
den(SW), Italy(IT), Spain(SP), Portugal(P) and Austria(A)
were involved in the study. The management of ischemic
events was analysed during the acute phase and the sub-
sequent 6-month periods. A decision tree was used; as-
sumptions concerning patient management and resources
utilization were based on currently available local and in-
ternational literature, official national statistics and local
expert opinions (Delphi panel). The costing was per-
formed by using Diagnosis Related Groups (IT,SW,P,A),
hospital data bases and national tariffs (F, B, CH, SP).
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RESULTS: Differences between countries about the average
clinical management patterns for a 2-year period are shown.
The economic impact concerns the overall cost (Ac  Fup)
as well as the breakdown between Ac and Fup costs. For
MI, overall costs range from 9513 Euros in Belgium to
18294 Euros in Austria. Weights of the follow-up costs
range from 33% in Portugal to 53% in Austria. For IS,
overall costs range from 5607 Euros in Austria to 56370
Euros in Switzerland. Differences also concern the weight of
the Fup costs (from 17% in Portugal to 75% in France).
CONCLUSION: Differences in overall cost and cost
breakdown can be explained by local treatment pattern
specificities and by the availability of specific and well-
adapted structures for patients rehabilitation. The follow-
up of an ischemic event should not be neglected in the glo-
bal economic burden assessment.
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OBJECTIVES: To i) compare the relative costs of two
leading atypical antipsychotics and ii) examine the contri-
bution of cost drivers of inpatient schizophrenia care.
METHODS: Data were pooled from a series of retrospec-
tive, single centre studies across 11 centers within 5 coun-
tries. Only patients with a diagnosis of schizophrenia or
schizoaffective disorder were considered.
RESULTS: A total of 601 patients received either risperi-
done (RIS; n  290) or olanzapine (OLA; n  311) as first
line therapy after admission. There were no baseline differ-
ences between both groups. The two products showed
equivalent efficacy rates (RIS: 78%, OLA: 77%; p  0.8)
but RIS patients achieved efficacy sooner (median  10
days) than OLA patients (median  18 days; p  0.001).
The mean modal daily doses were 4.9 mg (RIS) and 14.9
mg (OLA). OLA patients were more expensive (USD) than
RIS patients in both daily treatment costs (RIS: mean 
3.3; OLA: mean  6.5; p  0.0001) and daily all medica-
tion costs (RIS: mean  4.2; OLA: mean  7.3; p 
0.0001). The contribution of cost drivers was examined
through regression on the two key inpatient cost outcomes,
daily all medications costs (log transformed) and length of
stay (LOS; censored Cox regression). Daily all medication
costs were independently affected by prior hospitalizations
(), choice of atypical (OLA higher than RIS) and dose of
atypical () and these findings were over and above certain
intermediate factors. Length of stay was affected by prior
hospitalizations (-) and dose of atypical () again over and
above certain intermediate factors. Despite being counter-
intuitive, the data clearly indicate that 1st episode patients
stayed longest and the duration of stay continued to reduce
with further admissions.
CONCLUSION: The choice and dose of atypical is a ma-
jor driver of inpatient therapy cost. In addition the prior
disease span and severity, as measured by previous hospi-
talizations, is an important predictor of inpatient care
costs.
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BACKGROUND: Some observational studies have not
confirmed the beneficial effects of antihypertensive drug
treatment on the incidence of stroke and coronary heart
disease as demonstrated in randomized controlled clinical
trials (RCTs). This contradiction is probably due to the bi-
ased comparison in most observational studies between
treated hypertensive patients and prognostically different
reference groups such as normotensives or untreated hyper-
tensives regardless of their severity of hypertension and co-
existence of other cardiovascular risk factors.
OBJECTIVE: To assess the effect of the pharmacologic
treatment of hypertension under everyday circumstances
on the incidence of stroke.
METHODS: Approximately 45 000 men and women aged
20 years were examined in 2 population-based studies in
the Netherlands. A cohort of 2616 hypertensive subjects
who were either pharmacologically treated for hyperten-
sion (n  1318) or untreated hypertensives who were “can-
didates” for pharmacologic treatment on the basis of the
severity of their hypertension and the presence of other car-
diovascular risk factors (n  983) was followed up for a
mean duration of 4.6 years and follow-up was complete for
2369 (91%) subjects.
RESULTS: In this observational study, compared to un-
treated hypertensive subjects who were “candidates” for
pharmacologic treatment, subjects who were pharmacolog-
ically treated for hypertension had, after adjustment for dif-
ferences in prognostic factors, a 39% [95% confidence in-
terval (CI): 3–61%] reduced risk of stroke. About 46 [95%
CI: 29–599] hypertensive patients need to be treated phar-
macologically for 5 years to prevent one stroke in the gen-
eral Dutch population.
CONCLUSION: When a prognostically comparable refer-
ence group is used, the pharmacological treatment of hy-
pertension under everyday circumstances appears to be ef-
fective in the reduction of the incidence of stroke. The
